Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
0.7270
-0.0230 (-3.07%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Ironwood Pharmaceuticals Stock Forecast
IRWD's stock price has decreased by -90.79% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Ironwood Pharmaceuticals stock have an average target of 4.94, with a low estimate of 0.70 and a high estimate of 14. The average target predicts an increase of 579.50% from the current stock price of 0.73.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ironwood Pharmaceuticals stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $7 → $1 | Buy → Hold | Downgrades | $7 → $1 | +37.55% | Apr 15, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $8 → $0.7 | Strong Buy → Hold | Downgrades | $8 → $0.7 | -3.71% | Apr 15, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $3 → $1 | Hold | Maintains | $3 → $1 | +37.55% | Apr 14, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $23 → $14 | Buy | Maintains | $23 → $14 | +1,825.72% | Jan 30, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +1,000.41% | Jan 22, 2025 |
Financial Forecast
Revenue This Year
274.58M
from 351.41M
Decreased by -21.86%
Revenue Next Year
268.11M
from 274.58M
Decreased by -2.36%
EPS This Year
0.18
from 0.01
Increased by 3,096.47%
EPS Next Year
0.16
from 0.18
Decreased by -7.30%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 287.5M | 295.4M | 297.2M | ||
| Avg | 274.6M | 268.1M | 262.7M | ||
| Low | 258.7M | 237.2M | 227.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -18.2% | 7.6% | 10.8% | ||
| Avg | -21.9% | -2.4% | -2.0% | ||
| Low | -26.4% | -13.6% | -15.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.22 | 0.24 | 0.38 | ||
| Avg | 0.18 | 0.16 | 0.22 | ||
| Low | 0.10 | 0.06 | 0.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3,886.6% | 37.8% | 130.7% | ||
| Avg | 3,096.5% | -7.3% | 36.9% | ||
| Low | 1,671.8% | -66.7% | -52.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.